17D Stock Overview
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Arcadia Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$5.95 |
| 52 Week Low | US$1.75 |
| Beta | 0.61 |
| 1 Month Change | -15.87% |
| 3 Month Change | -20.45% |
| 1 Year Change | -68.18% |
| 3 Year Change | -97.97% |
| 5 Year Change | -99.16% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 17D | DE Food | DE Market | |
|---|---|---|---|
| 7D | -8.4% | 0.01% | 1.2% |
| 1Y | -68.2% | -24.3% | 2.0% |
Return vs Industry: 17D underperformed the German Food industry which returned -24.3% over the past year.
Return vs Market: 17D underperformed the German Market which returned 2% over the past year.
Price Volatility
| 17D volatility | |
|---|---|
| 17D Average Weekly Movement | 8.6% |
| Food Industry Average Movement | 4.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 17D's share price has been volatile over the past 3 months.
Volatility Over Time: 17D's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 21 | Stan Jacot | www.arcadiabio.com |
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Arcadia Biosciences, Inc. Fundamentals Summary
| 17D fundamental statistics | |
|---|---|
| Market cap | €2.66m |
| Earnings (TTM) | -€12.30m |
| Revenue (TTM) | €4.98m |
0.5x
P/S Ratio-0.2x
P/E RatioIs 17D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 17D income statement (TTM) | |
|---|---|
| Revenue | US$5.33m |
| Cost of Revenue | US$4.24m |
| Gross Profit | US$1.09m |
| Other Expenses | US$14.25m |
| Earnings | -US$13.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -9.66 |
| Gross Margin | 20.39% |
| Net Profit Margin | -246.90% |
| Debt/Equity Ratio | 0% |
How did 17D perform over the long term?
See historical performance and comparison